166 related articles for article (PubMed ID: 21694724)
1. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
[No Abstract] [Full Text] [Related]
2. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.
Si L; Kong Y; Xu X; Flaherty KT; Sheng X; Cui C; Chi Z; Li S; Mao L; Guo J
Eur J Cancer; 2012 Jan; 48(1):94-100. PubMed ID: 21788131
[TBL] [Abstract][Full Text] [Related]
3. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
4. An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.
Panka DJ; Sullivan RJ; Mier JW
Melanoma Res; 2010 Oct; 20(5):401-7. PubMed ID: 20679909
[TBL] [Abstract][Full Text] [Related]
5. Pleural metastasis from auricular melanoma: A brief report.
Straccia P; Martini M; Pierconti F
Diagn Cytopathol; 2020 Apr; 48(4):376-379. PubMed ID: 31846216
[TBL] [Abstract][Full Text] [Related]
6. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the role of autophagy in melanoma.
Li S; Song Y; Quach C; Nemecio D; Liang C
Autophagy; 2019 Oct; 15(10):1843-1844. PubMed ID: 31242070
[TBL] [Abstract][Full Text] [Related]
8. [Paradigmatic shift in oncology: individualized melanoma treatment].
Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Lakartidningen; 2011 May 18-24; 108(20):1092-3. PubMed ID: 21815339
[No Abstract] [Full Text] [Related]
9. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression.
Ehsani L; Cohen C; Fisher KE; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):648-51. PubMed ID: 25046227
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA
Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205
[TBL] [Abstract][Full Text] [Related]
11. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
Bonet C; Giuliano S; Ohanna M; Bille K; Allegra M; Lacour JP; Bahadoran P; Rocchi S; Ballotti R; Bertolotto C
J Biol Chem; 2012 Aug; 287(35):29887-98. PubMed ID: 22767597
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
[TBL] [Abstract][Full Text] [Related]
14. Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma.
Sobrevilla-Moreno N; Rivera-Sánchez D; García-Ortega D; López-Macías D; Garcilazo-Reyes A; Álvarez-Avitia M
Oncology (Williston Park); 2021 Sep; 35(9):562-566. PubMed ID: 34529396
[No Abstract] [Full Text] [Related]
15. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
16. Distant metastasis due to heavily pigmented epithelioid melanoma with underlying BRAF V600E, NOTCH1, ERBB3, and PTEN mutations.
Motaparthi K; George EV; Guo R
J Cutan Pathol; 2019 Aug; 46(8):613-618. PubMed ID: 31025390
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S
PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
19. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.
Ziogas DC; Diamantopoulos P; Benopoulou O; Anastasopoulou A; Bafaloukos D; Stratigos AJ; Kirkwood JM; Gogas H
Oncologist; 2020 Aug; 25(8):e1209-e1220. PubMed ID: 32271498
[TBL] [Abstract][Full Text] [Related]
20. Targeting BRAF for patients with melanoma.
Arkenau HT; Kefford R; Long GV
Br J Cancer; 2011 Feb; 104(3):392-8. PubMed ID: 21139585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
